Acute kidney injury (AKI) remains a significant cause of morbidity and mortality following cardiac surgery. Through a more thorough understanding of perioperative genomics and the evolving role of early biomarkers ofAKI, the authors seek to improve meaningful outcomes among cardiac surgery patients. In this review, the focus will be on advances in risk stratification, evolving definitions and improving early diagnosis of AKI, identification of effective individualized therapies, and future directions.
Conlon PJ, Stafford-Smith M., White WD, et al. Acute renal failure following cardiac surgery. Nephrol Dial Transplant. 1999;14:1158-1162.
2.
Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A., Herskowitz A., Mangano DTRenal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med. 1998 ;128:194-203.
Loef BG, Epema AH, Smilde TD, et al. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. J Am Soc Nephrol. 2005;16:195-200.
5.
Chertow GM, Burdick E., Honour M., Bonventre JV, Bates DWAcute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16:3365-3370.
6.
Praught ML, Shlipak MGAre small changes in serum creatinine an important risk factor? Curr Opin Nephrol Hypertens. 2005;14:265-270.
7.
Nash K., Hafeez A., Hou S.Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930-936.
8.
Swaminathan M., Shaw AD, Phillips-Bute BG, et al. Trends in acute renal failure associated with coronary artery bypass graft surgery in the United States. Crit Care Med. 2007;35:2286-2291.
9.
Thakar CV, Arrigain S., Worley S., Yared JP, Paganini EPA clinical score to predict acute renal failure after cardiac surgery. J Am Soc Nephrol. 2005;16:162-168.
10.
Wijeysundera DN, Karkouti K., Dupuis JY, et al. Derivation and validation of a simplified predictive index for renal replacement therapy after cardiac surgery. JAMA. 2007;297:1801-1809.
11.
Palomba H., de Castro I., Neto AL, Lage S., Yu L.Acute kidney injury prediction following elective cardiac surgery: AKICS score . Kidney Int. 2007;72:624-631.
12.
Uchino S., Bellomo R., Morimatsu H., et al. External validation of severity scoring systems for acute renal failure using a multinational database. Crit Care Med. 2005; 33:1961-1967.
13.
Candela-Toha A., Elias-Martin E., Abraira V., et al. Predicting acute renal failure after cardiac surgery: external validation of two new clinical scores. Clin J Am Soc Nephrol. 2008;3:1260-1265.
14.
Stafford-Smith M.Perioperative renal dysfunction: implications and strategies for protection . In: Newman MF, ed. Perioperative Organ Protection. Baltimore, MD: Lippincott Williams & Wilkins;2003:89-124.
15.
Laffey JG, Boylan JF, Cheng DCThe systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology. 2002;97:215-252.
16.
Meldrum DR, Donnahoo KKRole of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res. 1999;85:185-199.
17.
Brull DJ, Montgomery HE, Sanders J., et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol. 2001;21:1458-1463.
18.
Gaudino M., Di Castelnuovo A., Zamparelli R., et al. Genetic control of postoperative systemic inflammatory reaction and pulmonary and renal complications after coronary artery surgery. J Thorac Cardiovasc Surg. 2003;126:1107-1112.
19.
Stafford-Smith M., Podgoreanu M., Swaminathan M., et al. Association of genetic polymorphisms with risk of renal injury after coronary bypass graft surgery. Am J Kidney Dis. 2005;45:519-530.
20.
Jaber BL, Rao M., Guo D., et al. Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine. 2004;25:212-219.
21.
Treszl A., Toth-Heyn P., Kocsis I., et al. Interleukin genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol. 2002 ;17:713-717.
22.
Isbir SC, Tekeli A., Ergen A., et al. Genetic polymorphisms contribute to acute kidney injury after coronary artery bypass grafting. Heart Surg Forum. 2007;10:E439-E444.
23.
Chew ST, Newman MF, White WD, et al. Preliminary report on the association of apolipoprotein E polymorphisms, with postoperative peak serum creatinine concentrations in cardiac surgical patients. Anesthesiology. 2000;93:325-331.
24.
MacKensen GB , Swaminathan M., Ti LK, et al. Preliminary report on the interaction of apolipoprotein E polymorphism with aortic atherosclerosis and acute nephropathy after CABG. Ann Thorac Surg. 2004;78:520-526.
25.
Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180-184.
26.
Yates RB, Stafford-Smith M.The genetic determinants of renal impairment following cardiac surgery. Semin Cardiothorac Vasc Anesth. 2006;10:314-326.
27.
Perianayagam MC, Liangos O., Kolyada AY, et al. NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18:255-263.
28.
Luo HD, Ramirez SP, Costa MD, et al. Preoperative microalbuminuria, haptoglobin phenotype 2-2, and age are independent predictors for acute renal failure following coronary artery bypass graft. Ann Acad Med Singapore. 2004;33(5 suppl):S15-S16.
29.
Lameire N., Hoste E.Reflections on the definition, classification, and diagnostic evaluation of acute renal failure. Curr Opin Crit Care. 2004;10:468-475.
30.
Ferguson TB Jr, Dziuban SW Jr, Edwards FH, et al. The STS National Database: current changes and challenges for the new millennium. Committee to Establish a National Database in Cardiothoracic Surgery, The Society of Thoracic Surgeons. Ann Thorac Surg. 2000;69:680-691.
31.
Bellomo R., Ronco C., Kellum JA, Mehta RL, Palevsky P.Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-R212.
32.
Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
33.
Lassnigg A. , Schmid ER, Hiesmayr M., et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med. 2008;36:1129-1137.
34.
Bagshaw SM, George C., Bellomo R.A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2008 ;23: 1569-1574.
Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005; 365:1231-1238.
39.
Dent CL, Ma Q., Dastrala S., et al. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care. 2007;11:R127.
40.
Wagener G., Jan M., Kim M., et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology. 2006;105:485-491.
41.
Bennett M., Dent CL, Ma Q., et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin JAm Soc Nephrol. 2008;3:665-673.
42.
Wagener G., Gubitosa G., Wang S., Borregaard N., Kim M., Lee HTIncreased incidence of acute kidney injury with aprotinin use during cardiac surgery detected with urinary NGAL. Am J Nephrol. 2008;28:576-582.
43.
Parikh CR, Mishra J., Thiessen-Philbrook H., et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006;70: 199-203.
44.
Mehta RLUrine IL-18 levels as a predictor of acute kidney injury in intensive care patients. Nat Clin Pract Nephrol. 2006;2:252-253.
45.
Parikh CR, Abraham E., Ancukiewicz M., Edelstein CLUrine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16:3046-3052.
46.
Parikh CR, Jani A., Melnikov VY, Faubel S., Edelstein CLUrinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43:405-414.
47.
Han WK, Bailly V., Abichandani R., Thadhani R., Bonventre JVKidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62:237-244.
48.
Ichimura T. , Asseldonk EJ, Humphreys BD, Gunaratnam L., Duffield JS, Bonventre JVKidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest. 2008;118:1657-1668.
49.
Ichimura T. , Hung CC, Yang SA, Stevens JL, Bonventre JVKidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol. 2004;286:F552-F563.
50.
Liangos O., Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18:904-912.
51.
Liangos O., Han WK, Wald R., et al. Urinary kidney injury molecule-1 level is an early and sensitive marker of acute kidney injury [Abstract]. J Am Soc Nephrol . 2006;17:403A.
52.
Han WK, Waikar SS, Johnson A., Curhan GC, Devarajan P., Bonventre JVUrinary biomarkers for early detection of acute kidney injury [Abstract]. J Am Soc Nephrol. 2006;17:403A.
53.
Herget-Rosenthal S., Marggraf G., Husing J., et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66:1115-1122.
54.
Dharnidharka VR, Kwon C., Stevens G.Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221-226.
55.
Van de Voorde RG, Katlman TI, Ma Q., et al. Serum NGAL and cystatin C as predictive biomarkers for acute kidney injury [Abstract]. J Am Soc Nephrol . 2006;17:404A.
56.
Koyner JL, Bennett MR, Worcester EM, et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int. 2008;74:1059-1069.
57.
Mitsnefes MM, Kathman TS, Mishra J., et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol. 2007;22:101-108.
58.
Pisitkun T., Johnstone R., Knepper MADiscovery of urinary biomarkers. Mol Cell Proteomics. 2006;5:1760-1771.
59.
Coca SG, Parikh CRUrinary biomarkers for acute kidney injury: perspectives on translation. Clin J Am Soc Nephrol. 2008;3:481-490.
60.
Moran SM, Myers BDPathophysiology of protracted acute renal failure in man. J Clin Invest. 1985;76:1440-1448.
61.
Shaw AD, Stafford-Smith M., White WD, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008;358:784-793.
62.
Star R.Design issues for clinical trials in acute renal failure. Blood Purif. 2001;19:233-237.
Zacharias M. , Gilmore IC, Herbison GP, Sivalingam P., Walker RJInterventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev. 2005;(3):CD003590.
68.
Kristal B., Shurtz-Swirski R., Tanhilevski O., et al. Epoetin-alpha: preserving kidney function via attenuation of polymorphonuclear leukocyte priming. Isr Med Assoc J. 2008;10:266-272.
69.
Joyeux-Faure M.Cellular protection by erythropoietin: new therapeutic implications? J Pharmacol Exp Ther. 2007;323:759-762.
70.
ClinicalTrials.gov. NCT00654992. Effect of erythropoietin in kidney after cardiac surgery (EPO-CABG). http://clinicaltrials.gov/ct2/show/NCT00654992. Accessed July 4, 2008.
71.
ClinicalTrials.gov. NCT00676234. Recombinant human erythropoietin use in intensive care unit (ICU) patients: does it prevent acute renal failure. http://clinicaltrials.gov/ct2/show/NCT00676234. Accessed July 4, 2008.
72.
Australian New Zealand Clinical Trials Registry. ACTRN12606000058572. Early intervention in acute renal failure. http://www.anzctr.org.au/trial_view.aspx?ID=1009. Accessed July 4, 2008.
73.
Kelly KJ, Sutton TA, Weathered N., et al. Minocycline inhibits apoptosis and inflammation in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2004;287:F760-F766.
74.
Sutton TA, Kelly KJ, Mang HE, Plotkin Z., Sandoval RM, Dagher PCMinocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2005;288:F91-F97.
75.
ClinicalTrials.gov. NCT00556491. Minocycline to prevent acute kidney injury after cardiac surgery. http://clinical-trials.gov/ct2/show/NCT00556491. Accessed July 4, 2008.
76.
Nushiro N., Abe K., Misawa S., et al. The effects of intrarenal infusion of recombinant human erythropoietin on mean arterial pressure and renal hemodynamics in anesthetized rabbits. Tohoku J Exp Med. 1992;167:19-25.
77.
Froba G., Bracht H., Hauser B., et al. Effects of intrarenal administration of the calcium antagonist nimodipine during porcine aortic occlusion-induced ischemia/reperfusion injury . Shock. 2008;29:717-723.
78.
Badzynska B. , Sadowski J.Renal hemodynamic responses to intrarenal infusion of acetylcholine: comparison with effects of PGE2 and NO donor. Kidney Int. 2006;69:1774-1779.
79.
Cogliati AA , Vellutini R., Nardini A., et al. Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study. J Cardiothorac Vasc Anesth. 2007;21:847-850.
80.
Allie DE, Hebert CJ, Walker CMMultifactorial acute renal failure treated with percutaneous targeted renal therapy (TRT): a case of "dialysis rescue." J Invasive Cardiol . 2007;19:E27-E30.
81.
Allie DE, Lirtzman MD, Wyatt CH, et al. Targeted renal therapy and contrast-induced nephropathy during endovascular abdominal aortic aneurysm repair: results of a feasibility pilot trial. J Endovasc Ther. 2007;14:520-527.
82.
Ng MK, Tremmel J., Fitzgerald PJ, Fearon WFSelective renal arterial infusion of fenoldopam for the prevention of contrast-induced nephropathy. J Interv Cardiol. 2006;19:75-79.
83.
ClinicalTrials.gov. NCT00672334. Sodium bicarbonate in cardiac surgery study (Bic-MC). http://clinicaltrials.gov/ct2/show/NCT00672334. Accessed July 4, 2008.
84.
ClinicalTrials.gov. NCT00522756. Preventing acute renal failure after cardiac surgery in high risk patients using sodium bicarbonate therapy (PARACHUTE). http://clinicaltrials.gov/ct2/show/NCT00522756 . Accessed July 4, 2008.
85.
ClinicalTrials.gov. NCT00188630. N-Acetylcysteine for preventing renal injury after cardiac surgery. http://clinicaltrials.gov/ct2/show/NCT00188630. Accessed July 4, 2008.
86.
ClinicalTrials.gov. NCT00394303. Tight intra-operative glucose control during coronary artery bypass surgery . http://clinicaltrials.gov/ct2/show/NCT00394303 . Accessed July 4, 2008.
